compounded semaglutide being discontinued 📢 FDA has determined the shortage of injection products, a glucagon-like peptide 1 (GLP-1) medication, is resolved. Patients and prescribers may still see intermittent and limited localized supply disruptions as the FDA issues warning about some

Insurance coverage for weight loss medications remains limited, retail prices for FDA-approved GLP-1 drugs continue to be out of reach for many patients, and consumer adoption of telehealth prescription services increased significantly following widespread use during the pandemic

GLP-1 medications demonstrates notable differences in their modes of action

The efficacy of liraglutide 3.0 mg as an adjunct to diet and exercise was also evaluated in 3731 non-diabetic patients presenting with a BMI 27 (in the presence of dyslipidemia or hypertension) or 30 kg/m 2 treated for 56 weeks

Not all interventions are pharmacologic